Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned an average rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $215.3846.

Several analysts have weighed in on JAZZ shares. Truist Financial upgraded Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Bank of America upped their target price on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Piper Sandler increased their price target on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th.

Jazz Pharmaceuticals Trading Down 3.4%

NASDAQ JAZZ opened at $182.69 on Friday. Jazz Pharmaceuticals has a 12-month low of $95.49 and a 12-month high of $198.00. The company has a fifty day simple moving average of $175.63 and a two-hundred day simple moving average of $160.05. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The stock has a market cap of $11.25 billion, a P/E ratio of -30.60, a P/E/G ratio of 0.33 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating analysts’ consensus estimates of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the company earned $6.51 earnings per share. On average, analysts forecast that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 55,600 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the completion of the transaction, the executive vice president directly owned 56,862 shares in the company, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the sale, the senior vice president directly owned 28,728 shares in the company, valued at approximately $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 68,015 shares of company stock valued at $13,037,486 over the last quarter. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $858,000. Corient Private Wealth LLC raised its position in Jazz Pharmaceuticals by 91.1% during the fourth quarter. Corient Private Wealth LLC now owns 10,200 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after acquiring an additional 4,863 shares in the last quarter. DGS Capital Management LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $260,000. Pacer Advisors Inc. lifted its holdings in Jazz Pharmaceuticals by 19.8% in the fourth quarter. Pacer Advisors Inc. now owns 647,084 shares of the specialty pharmaceutical company’s stock valued at $110,004,000 after acquiring an additional 107,144 shares during the period. Finally, Kera Capital Partners Inc. purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $336,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.